These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35691416)

  • 1. The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs.
    Fugger G; Bartova L; Fabbri C; Fanelli G; Zanardi R; Dold M; Kautzky A; Rujescu D; Souery D; Mendlewicz J; Zohar J; Montgomery S; Serretti A; Kasper S
    J Affect Disord; 2022 Sep; 312():225-234. PubMed ID: 35691416
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimal use of antidepressants: when to act?
    Blier P
    J Psychiatry Neurosci; 2009 Jan; 34(1):80. PubMed ID: 19125216
    [No Abstract]   [Full Text] [Related]  

  • 3. Mirtazapine: a review of its use in major depression and other psychiatric disorders.
    Croom KF; Perry CM; Plosker GL
    CNS Drugs; 2009; 23(5):427-52. PubMed ID: 19453203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of mirtazapine in a patient with chronic pain.
    Brannon GE; Stone KD
    J Pain Symptom Manage; 1999 Nov; 18(5):382-5. PubMed ID: 10584463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidepressant switching among adherent patients treated for depression.
    Marcus SC; Hassan M; Olfson M
    Psychiatr Serv; 2009 May; 60(5):617-23. PubMed ID: 19411348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mirtazapine for treatment-resistant depression: a preliminary report.
    Wan DD; Kundhur D; Solomons K; Yatham LN; Lam RW
    J Psychiatry Neurosci; 2003 Jan; 28(1):55-9. PubMed ID: 12587851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comments on "Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder".
    Pae CU
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):597-8. PubMed ID: 17919799
    [No Abstract]   [Full Text] [Related]  

  • 8. Wuling Capsule for Major Depressive Disorder: A Meta-analysis of Randomised Controlled Trials.
    Zheng W; Zhang YF; Zhong HQ; Mai SM; Yang XH; Xiang YT
    East Asian Arch Psychiatry; 2016 Sep; 26(3):87-97. PubMed ID: 27703096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of mirtazapine on sleep polygraphic variables in major depression.
    Schittecatte M; Dumont F; Machowski R; Cornil C; Lavergne F; Wilmotte J
    Neuropsychobiology; 2002; 46(4):197-201. PubMed ID: 12566938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Occurrence of mirtazapine-induced delirium in organic brain disorder.
    Bailer U; Fischer P; Küfferle B; Stastny J; Kasper S
    Int Clin Psychopharmacol; 2000 Jul; 15(4):239-43. PubMed ID: 10954066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder.
    Kang RH; Wong ML; Choi MJ; Paik JW; Lee MS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1317-21. PubMed ID: 17618721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mirtazapine for depression in patients with human immunodeficiency virus.
    Elliott AJ; Roy-Byrne PP
    J Clin Psychopharmacol; 2000 Apr; 20(2):265-7. PubMed ID: 10770469
    [No Abstract]   [Full Text] [Related]  

  • 13. [Combining venlafaxine and mirtazapine for the treatment of major depression with dysthymia--"double depression"].
    Ladeira RB; Cunha FT; Salgado JV; Teixeira AL; Nicolato R
    Braz J Psychiatry; 2008 Sep; 30(3):299-300. PubMed ID: 18833439
    [No Abstract]   [Full Text] [Related]  

  • 14. A risk-benefit assessment of mirtazapine in the treatment of depression.
    Kasper S; Praschak-Rieder N; Tauscher J; Wolf R
    Drug Saf; 1997 Oct; 17(4):251-64. PubMed ID: 9352961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is a rational antidepressant treatment for major depression in patients with Parkinson's disease?
    Hagikura M; Iwamoto K; Aleksic B; Ozaki N
    Psychiatry Clin Neurosci; 2012 Aug; 66(5):463. PubMed ID: 22834671
    [No Abstract]   [Full Text] [Related]  

  • 16. Functional dyspepsia and mirtazapine.
    Lee SY; Rho SH; Choi SC
    Can J Psychiatry; 2002 Aug; 47(6):582-3. PubMed ID: 12211889
    [No Abstract]   [Full Text] [Related]  

  • 17. Re-administration of mirtazapine could overcome previous mirtazapine- associated restless legs syndrome?
    Pae CU; Kim TS; Kim JJ; Chae JH; Lee CU; Lee SJ; Paik IH; Lee C
    Psychiatry Clin Neurosci; 2004 Dec; 58(6):669-70. PubMed ID: 15601394
    [No Abstract]   [Full Text] [Related]  

  • 18. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.
    McGrath PJ; Stewart JW; Fava M; Trivedi MH; Wisniewski SR; Nierenberg AA; Thase ME; Davis L; Biggs MM; Shores-Wilson K; Luther JF; Niederehe G; Warden D; Rush AJ
    Am J Psychiatry; 2006 Sep; 163(9):1531-41; quiz 1666. PubMed ID: 16946177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression.
    Kent JM
    Lancet; 2000 Mar; 355(9207):911-8. PubMed ID: 10752718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of mirtazapine on sleep in patients with major depressive disorder.
    Dolder CR; Nelson MH; Iler CA
    Ann Clin Psychiatry; 2012 Aug; 24(3):215-24. PubMed ID: 22860241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.